Enhanced efficiency of prodrug activation therapy by tumor-selective replicating retrovirus vectors armed with the Escherichia coli purine nucleoside phosphorylase gene

Cancer Gene Therapy

Volumn 17, Issue 9, 2010, Pages 614-623

  Tai, C K ^a,b   Wang, W ^c   Lai, Y H ^a   Logg, C R ^b   Parker, W B ^d   Li, Y F ^e   Hong, J S ^f   Sorscher, E J ^g   Chen, T C ^c   Kasahara, N ^b  

^a NATIONAL CHUNG CHENG UNIVERSITY   (Taiwan)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d SOUTHERN RESEARCH INSTITUTE   (United States)

^e CHINA MEDICAL UNIVERSITY   (Taiwan)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^g University of Alabama at Birmingham   (United States)

Author keywords

brain tumor; oncolytic therapy; purine nucleoside phosphorylase; Retrovirus; suicide gene

Indexed keywords

FLUDARABINE PHOSPHATE; PRODRUG; PURINE NUCLEOSIDE PHOSPHORYLASE; RETROVIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GENE THERAPY; CANCER INHIBITION; CANCER MODEL; CANCER SURVIVAL; CELL KILLING; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; ENZYME ACTIVITY; ESCHERICHIA COLI; GENE EXPRESSION; GLIOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INOCULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUICIDE GENE THERAPY; SURVIVAL TIME; TRANSGENE; TREATMENT OUTCOME; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM; VIRUS REPLICATION;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ESCHERICHIA COLI; GENE THERAPY; GENETIC VECTORS; GLIOMA; GREEN FLUORESCENT PROTEINS; HUMANS; INJECTIONS, INTRALESIONAL; INJECTIONS, SUBCUTANEOUS; MICE; MICE, NUDE; PRODRUGS; PURINE-NUCLEOSIDE PHOSPHORYLASE; RETROVIRIDAE; VIDARABINE PHOSPHATE;

ESCHERICHIA COLI;

EID: 77955921276     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2010.17     Document Type: Article

References (35)

1. Parker WB, Allan PW, Shaddix SC, Rose LM, Speegle HF, Gillespie GY et al. Metabolism and metabolic actions of 6-methylpurine and 2-fluoroadenine in human cells. Biochem Pharmacol 1998; 55: 1673-1681.
2. Hong JS, Waud WR, Levasseur DN, Townes TM, Wen H, McPherson SA et al. Excellent in vivo bystander activity of fludarabine phosphate against human glioma xenografts that express the Escherichia coli purine nucleoside phosphorylase gene. Cancer Res 2004; 64: 6610-6615.
3. Sorscher EJ, Peng S, Bebok Z, Allan PW, Bennett Jr LL, Parker WB. Tumor cell bystander killing in colonic carcinoma utilizing the Escherichia coli DeoD gene to generate toxic purines. Gene Ther 1994; 1: 233-238.
4. Mohr L, Shankara S, Yoon SK, Krohne TU, Geissler M, Roberts B et al. Gene therapy of hepatocellular carcinoma in vitro and in vivo in nude mice by adenoviral transfer of the Escherichia coli purine nucleoside phosphorylase gene. Hepatology 2000; 31: 606-614.
5. Voeks D, Martiniello-Wilks R, Madden V, Smith K, Bennetts E, Both GW et al. Gene therapy for prostate cancer delivered by ovine adenovirus and mediated by purine nucleoside phosphorylase and fludarabine in mouse models. Gene Ther 2002; 9: 759-768.
6. Parker WB, King SA, Allan PW, Bennett Jr LL, Secrist III JA, Montgomery JA et al. In vivo gene therapy of cancer with E. coli purine nucleoside phosphorylase. Hum Gene Ther 1997; 8: 1637-1644.
7. Martiniello-Wilks R, Dane A, Voeks DJ, Jeyakumar G, Mortensen E, Shaw JM et al. Gene-directed enzyme prodrug therapy for prostate cancer in a mouse model that imitates the development of human disease. J Gene Med 2004; 6: 43-54.
8. Rainov NG. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther 2000; 11: 2389-2401.
9. Kirn D, Martuza RL, Zwiebel J. Replication-selective virotherapy for cancer: biological principles, risk management and future directions. Nat Med 2001; 7: 781-787.
10. Hermiston TW, Kuhn I. Armed therapeutic viruses: strategies and challenges to arming oncolytic viruses with therapeutic genes. Cancer Gene Ther 2002; 9: 1022-1035.
11. Logg CR, Tai CK, Logg A, Anderson WF, Kasahara N. A uniquely stable replication-competent retrovirus vector achieves efficient gene delivery in vitro and in solid tumors. Hum Gene Ther 2001; 12: 921-932.
12. Wang WJ, Tai CK, Kasahara N, Chen TC. Highly efficient and tumor-restricted gene transfer to malignant gliomas by replication-competent retroviral vectors. Hum Gene Ther 2003; 14: 117-127.
13. Tai CK, Logg CR, Park JM, Anderson WF, Press MF, Kasahara N. Antibody-mediated targeting of replication-competent retroviral vectors. Hum Gene Ther 2003; 14: 789-802.
14. Tai CK, Wang WJ, Chen TC, Kasahara N. Single-shot, multicycle suicide gene therapy by replication-competent retrovirus vectors achieves long-term survival benefit in experimental glioma. Mol Ther 2005; 12: 842-851.
15. Hiraoka K, Kimura T, Logg CR, Kasahara N. Tumor-selective gene expression in a hepatic metastasis model after locoregional delivery of a replication-competent retrovirus vector. Clin Cancer Res 2006; 12: 7108-7116.
16. Hiraoka K, Kimura T, Logg CR, Tai CK, Haga K, Lawson GW et al. Therapeutic efficacy of replication-competent retrovirus vector-mediated suicide gene therapy in a multi-focal colorectal cancer metastasis model. Cancer Res 2007; 67: 5345-5353.
17. Puhlmann M, Gnant M, Brown CK, Alexander HR, Bartlett DL. Thymidine kinase-deleted vaccinia virus expressing purine nucleoside phosphorylase as a vector for tumor-directed gene therapy. Hum Gene Ther 1999; 10: 649-657.
18. Logg CR, Logg A, Matusik RJ, Bochner BH, Kasahara N. Tissue-specific transcriptional targeting of a replication-competent retroviral vector. J Virol 2002; 76: 12783-12791.
19. DuBridge RB, Tang P, Hsia HC, Leong PM, Miller JH, Calos MP. Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system. Mol Cell Biol 1987; 7: 379-387.
20. Ponten J, Macintyre EH. Long term culture of normal and neoplastic human glia. Acta Pathol Microbiol Scand 1968; 74: 465-486.
21. Evans LH, Morrison RP, Malik FG, Portis J, Britt WJ. A neutralizable epitope common to the envelope glycoproteins of ecotropic, polytropic, xenotropic, and amphotropic murine leukemia viruses. J Virol 1990; 64: 6176-6183.
22. Parker WB, Allan PW, Hassan AE, Secrist III JA, Sorscher EJ, Waud WR. Antitumor activity of 2-fluoro-2-deoxyadenosine against tumors that express Escherichia coli purine nucleoside phosphorylase. Cancer Gene Ther 2003; 10: 23-29.
23. Gadi VK, Alexander SD, Kudlow JE, Allan P, Parker WB, Sorscher EJ. In vivo sensitization of ovarian tumors to chemotherapy by expression of E. coli purine nucleoside phosphorylase in a small fraction of cells. Gene Ther 2000; 7: 1738-1743.
24. Kruse CA, Roper MD, Kleinschmidt-DeMasters BK, Banuelos SJ, Smiley WR, Robbins JM et al. Purified herpes simplex thymidine kinase retrovector particles. I. In vitro characterization, in situ transduction efficiency, and histo-pathological analyses of gene therapy-treated brain tumors. Cancer Gene Ther 1997; 4: 118-128.
25. Gadi VK, Alexander SD, Waud WR, Allan PW, Parker WB, Sorscher EJ. A long-acting suicide gene toxin, 6-methylpur-ine, inhibits slow growing tumors after a single administration. J Pharmacol Exp Ther 2003; 304: 1280-1284.
26. Kikuchi E, Menendez S, Ozu C, Ohori M, Cordon-Cardo C, Logg CR et al. Delivery of replication-competent retrovirus expressing Escherichia coli purine nucleoside phosphorylase increases the metabolism of the prodrug, fludarabine phosphate and suppresses the growth of bladder tumor xenografts. Cancer Gene Ther 2007; 14: 279-286.
27. Wang XY, Martiniello-Wilks R, Shaw JM, Ho T, Coulston N, Cooke-Yarborough C et al. Preclinical evaluation of a prostate-targeted gene-directed enzyme prodrug therapy delivered by ovine atadenovirus. Gene Ther 2004; 11: 1559-1567.
28. Martiniello-Wilks R, Wang XY, Voeks DJ, Dane A, Shaw JM, Mortensen E et al. Purine nucleoside phosphor-ylase and fludarabine phosphate gene-directed enzyme prodrug therapy suppresses primary tumour growth and pseudo-metastases in a mouse model of prostate cancer. J Gene Med 2004; 6: 1343-1357.
29. Wang W, Tai CK, Kershaw AD, Solly SK, Klatzmann D, Kasahara N et al. Use of replication-competent retroviral vectors in an immunocompetent intracranial glioma model. Neurosurg Focus 2006; 20: E25.
30. Cornetta K, Morgan RA, Gillio A, Sturm S, Baltrucki L, O'Reilly R et al. No retroviremia or pathology in long-term follow-up of monkeys exposed to a murine amphotropic retrovirus. Hum Gene Ther 1991; 2: 215-219.
31. Cornetta K, Moen RC, Culver K, Morgan RA, McLachlin JR, Sturm S et al. Amphotropic murine leukemia retrovirus is not an acute pathogen for primates. Hum Gene Ther 1990; 1: 15-30.
32. Donahue RE, Kessler SW, Bodine D, McDonagh K, Dunbar C, Goodman S et al. Helper virus induced T cell lymphoma in nonhuman primates after retroviral mediated gene transfer. J Exp Med 1992; 176: 1125-1135.
33. Marshall E. Clinical research. Gene therapy a suspect in leukemia-like disease. Science 2002; 298: 34-35.
34. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302: 415-419.
35. Li Z, Dullmann J, Schiedlmeier B, Schmidt M, von Kalle C, Meyer J et al. Murine leukemia induced by retroviral gene marking. Science 2002; 296: 497.